Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) published the new Clinical Practice ...

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...

Chronic rhinosinusitis is one of the most common clinical syndromes in the USA. The etiology of chronic rhinosinusitis is probably multifactorial, including infectious agents, ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP ...

For an estimated 30 million American adults, the simple act of breathing can be a daily struggle. That’s one in eight adults ...

What makes the case unique: Since the 1930s, exostoses in the ear canal have been associated with surfing and other water activities that involve prolonged, repeated immersion in cold water.